Jose Miguel
Rivera Caravaca
Profesor Permanente Laboral
Liverpool Heart and Chest Hospital NHS Trust
Liverpool, Reino UnidoPublicaciones en colaboración con investigadores/as de Liverpool Heart and Chest Hospital NHS Trust (30)
2024
-
Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients
Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842
2023
-
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
Diabetes, Obesity and Metabolism, Vol. 25, Núm. 2, pp. 602-610
-
Molecular mechanisms of postoperative atrial fibrillation in patients with obstructive sleep apnea
FASEB Journal, Vol. 37, Núm. 6
-
The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323
2022
-
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry
Expert Opinion on Pharmacotherapy, Vol. 23, Núm. 12, pp. 1457-1465
-
Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry
European Journal of Clinical Investigation, Vol. 52, Núm. 4
-
Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry
Europace, Vol. 24, Núm. 2, pp. 202-210
-
Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence
British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 282-289
-
Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
Clinical Research in Cardiology, Vol. 111, Núm. 9, pp. 1040-1047
-
Predicting heart failure in atrial fibrillation patients: What about using biomarkers?
American Heart Journal
-
Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients
European Journal of Internal Medicine
-
Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
Journal of Personalized Medicine, Vol. 12, Núm. 3
-
Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial
Journal of Thrombosis and Thrombolysis, Vol. 54, Núm. 1, pp. 1-6
-
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study
European Journal of Clinical Investigation
2021
-
Antithrombotic therapy in patients with peripheral artery disease: A focused review on oral anticoagulation
International Journal of Molecular Sciences, Vol. 22, Núm. 13
-
Cardiovascular risk factors, cardiovascular disease, and COVID-19: An umbrella review of systematic reviews
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 7, Núm. 4, pp. 330-339
-
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
Thrombosis Research, Vol. 205, pp. 1-7
-
Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
Cardiovascular Diabetology, Vol. 20, Núm. 1
-
Gut microbiota and the quality of oral anticoagulation in vitamin K antagonists users: A review of potential implications
Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-16
-
Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs ‘real-world’
International Journal of Clinical Practice, Vol. 75, Núm. 4